Key result
Quinupristin/dalfopristin (RP 59500) was evaluated as a therapy for prosthetic valve endocarditis due to enterococci with VanA/VanB resistance patterns.
Key points are not available for this paper at this time.
No takes yet. Share an insight, caveat, or question.
Should not yet change practice for resistant enterococcal prosthetic valve endocarditis; leaves open efficacy pending controlled trials.
Furlong et al. (1997) studied this question. Quinupristin/dalfopristin (RP 59500) was evaluated as a therapy for prosthetic valve endocarditis due to enterococci with VanA/VanB resistance patterns.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: